QUESTIONS / STRAIGHT ANSWERS
Ipamorelin: the questions people actually ask
Short, direct, cited where there's a number. No dosing advice, no sales pitch.
Why is ipamorelin being discontinued?
Ipamorelin was never a marketed drug, so there's nothing to "discontinue" in the usual sense. Its development stalled because its only published Phase 2 trial — for postoperative ileus — missed its primary endpoint (first tolerated meal 25.3 h vs 32.6 h placebo, p=0.15) [3]. Separately, in 2024 the FDA tightened compounding-pharmacy access by removing ipamorelin acetate from the interim 503A bulk-substances Category 2.
Will I gain weight on ipamorelin?
The honest answer is uncertain and direction-dependent. Ipamorelin acts on the ghrelin (hunger) receptor and, in mice, stimulated adiposity and raised leptin independent of growth hormone [15]. In a 2024 ferret study it reduced chemotherapy-driven weight loss [5]. There is no human study of weight change at research-use doses, so any specific claim is unsupported. Community reports vary in both directions.
Does ipamorelin help with gut motility?
In animals, yes — that's its strongest preclinical story. Repeated IV ipamorelin raised fecal output, food intake, and weight gain in rats with surgical ileus, and a single dose shortened time to first bowel movement [11]. The related ghrelin-agonist class accelerates gastric emptying broadly [7][9]. But the one human gut trial (postoperative ileus) failed its primary endpoint [3], so animal motility did not translate to a human win.
What is ipamorelin?
Ipamorelin is a synthetic pentapeptide (Aib-His-D-2-Nal-D-Phe-Lys-NH2) and a selective agonist of the ghrelin / growth hormone secretagogue receptor (GHS-R1a). In its founding study it released growth hormone potently in rats and swine (swine ED50 = 2.3 nmol/kg) without raising cortisol or ACTH, defining it as the first highly GH-selective secretagogue [1]. It has never been approved as a drug.
What does ipamorelin do for you?
In the research, ipamorelin triggers a single pulse of growth hormone by activating the ghrelin receptor, without the stress-hormone elevation of older peptides [1]. In animals it also speeds gut motility [11] and grows bone [4]. What it does in a healthy human at community doses has not been measured in controlled trials — the one human efficacy trial, for bowel surgery, failed [3].
What is ipamorelin peptide?
Ipamorelin peptide is a five-amino-acid (pentapeptide) chain, sequence Aib-His-D-2-Nal-D-Phe-Lys-NH2, derived from the older peptide GHRP-1 and engineered to resist enzymatic breakdown [1]. It is a ghrelin-receptor (GHS-R1a) agonist that releases growth hormone selectively. It is wholly synthetic — not a hormone the body produces — with a molecular weight around 712 Da [1].
What are the risks of ipamorelin?
The documented concerns are mostly mechanistic and class-level: GH-axis stimulation raises theoretical cancer/IGF-1 worries [1][4], can worsen glucose control [14], and a 28-day study of a related ghrelin agonist found heart-muscle damage in rats [6]. The biggest concrete risk is the unknown: no long-term human safety data exist, and the one human trial ran only 7 days [3]. Unregulated material adds purity risk.
Does ipamorelin reduce belly fat?
There's no human trial showing ipamorelin reduces belly fat. The controlled animal data actually point toward a ghrelin-driven push to adiposity and feeding [15][16]. The one weight-related finding is the 2024 ferret study, where ipamorelin reduced chemotherapy-induced weight loss — an anti-wasting effect, not fat loss [5]. Community leanness reports are anecdotal and confounded by diet and training.
What are the downsides of ipamorelin?
Beyond the unknown long-term safety [3], community-reported downsides include facial flushing after injecting, increased hunger, mild water retention, tingling in the extremities, injection-site irritation, and a fading response over months — all anecdotal, none from a trial. The mechanistic downsides (glucose effects [14], theoretical IGF-1/cancer concerns [1][4], a class cardiac signal [6]) are detailed on the effects page.
What does CJC-1295 and ipamorelin do?
Together, CJC-1295 (a GHRH analog) and ipamorelin (a ghrelin-receptor agonist) release growth hormone through two complementary receptors, which in principle produces a larger combined GH pulse than either alone [1]. No controlled human trial has tested the combination for any outcome [3], so its real-world effects on body composition, recovery, or sleep remain unproven extrapolation from single-agent pharmacology.
Does ipamorelin increase IGF-1?
Sometimes, and it's context-dependent. A GH pulse can drive the liver to make IGF-1, but in short rodent studies ipamorelin grew bone with no measurable change in total IGF-1 [4]. So IGF-1 elevation is not guaranteed and depends on dose, duration, and protocol. Sustained, repeated dosing is more likely to raise IGF-1 than a single pulse [1][4].
How does CJC-1295 ipamorelin work?
CJC-1295 mimics growth-hormone-releasing hormone (GHRH) and acts on the GHRH receptor; ipamorelin activates the separate ghrelin receptor (GHS-R1a) [1]. Because they hit two different receptors that both promote GH release, combining them can stack their effects into a bigger GH pulse [1]. The mechanism is sound at the receptor level, but the combination itself has never been tested in a controlled human trial [3].
How much CJC-1295 ipamorelin should I take?
No published human dosing exists for the cjc-1295 ipamorelin combination — no controlled trial has ever tested it at any dose [3], and this site recommends nothing. The community "stack" regimens in forums have no peer-reviewed human basis and are anecdotal practice, not a protocol. The only human ipamorelin dosing on record is intravenous research dosing [2].
Does CJC-1295 ipamorelin work?
Each component works pharmacologically — ipamorelin releases a clean GH pulse via the ghrelin receptor [1], and CJC-1295 prolongs GHRH-driven GH release. But whether the combination delivers the outcomes people want has never been tested in a controlled human trial [3]. For ipamorelin alone, the one human efficacy trial missed its endpoint [3]. "Works" applies to GH release, not to proven outcomes.
How to reconstitute CJC-1295 ipamorelin 5mg?
Ipamorelin ships as a lyophilized (freeze-dried) powder and is reconstituted with bacteriostatic water for research handling; as a peptide it degrades with heat and freeze-thaw, so solution is kept refrigerated [2]. These are general handling notes from the research-supply literature, not a clinical preparation instruction. There is no approved cjc-1295 ipamorelin product with a labeled preparation procedure.
How long does ipamorelin stay in your system?
Not long. In healthy human volunteers, ipamorelin had a terminal half-life of about 2 hours [2]. The growth hormone pulse it triggers peaks around 40 minutes after dosing and then subsides [2]. By the rule of thumb that most of a drug clears in about five half-lives, ipamorelin is largely gone within roughly 10 hours — though anti-doping detection windows differ from simple clearance.
Does ipamorelin make you hungry?
It can. Ipamorelin acts on the ghrelin (hunger) receptor, and ghrelin-receptor agonists induced feeding and activated brain appetite centers in animal studies [16]. Community reports describe a hunger uptick after injecting, generally milder than with GHRP-6 — anecdotal, not clinical. The effect rides a short window since ipamorelin clears in about 2 hours [2]. More on the appetite page.
Does ipamorelin increase appetite?
Mechanistically, yes, it's plausible: ipamorelin hits the same receptor as the hunger hormone ghrelin, and ghrelin-receptor agonists drove feeding in animal studies [16]. In mice it also raised adiposity and leptin independent of GH [15]. No human appetite trial exists at research doses, but the mechanism and community reports both point to an appetite-stimulating tendency [16][15].
What does ipamorelin peptide do?
Ipamorelin peptide selectively activates the ghrelin receptor (GHS-R1a) to release a single pulse of growth hormone, without raising cortisol or prolactin the way older peptides do [1]. In animals it also speeds gut motility [11], grows bone [4], and directly triggers pancreatic insulin release [14]. Its real-world effects in healthy humans are unproven — the one human efficacy trial failed [3].
How long does it take for ipamorelin to work?
At the level of hormone release, fast — the growth hormone pulse peaks about 40 minutes after a dose in humans [2]. At the level of effects people care about (sleep, recovery), community reports describe changes over one to two weeks, but these are anecdotal and unverified. There is no controlled human trial measuring an onset of benefit at research-use doses [3].
Does ipamorelin cause water retention?
Mild water retention is occasionally reported by users, typically described as milder than with older GH-releasing peptides and easing within the first weeks — anecdotal, not from a trial. The mechanistic basis is that GH excess (as in acromegaly) promotes sodium and water retention, so chronically raising GH could plausibly contribute [3]. No ipamorelin study has measured fluid balance directly at research doses.
Where to inject CJC-1295 ipamorelin?
This site does not provide injection instructions — it's an editorial research digest, not a clinical guide, and recommends no administration. For context only: in the literature, ipamorelin was given intravenously in human and rodent studies, and subcutaneously in rodent body-composition work [2][4]. There is no approved cjc-1295 ipamorelin product and no labeled route of administration to follow.